Clinical trial · Interventional
HEARTS Trial for Thoracic Cancers
The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart. The main question it aims to answer is whether MRgART affects the heart differently than LINAC. Participants will: * Receive radiation therapy * Undergo MRIs and bloodwork * Complete quality of life questionnaires
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer Stage I-III | — | UNRESOLVED | — |
| Esophagogastric Cancer Stage I-III | — | UNRESOLVED | — |
| Non-Small Cell Lung Cancer (Stage III) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
| Other Cancers in the Thoracic Region | — | UNRESOLVED | — |
| Thymoma and Thymic Carcinoma Stage II-III | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LINAC | Radiation | — | UNRESOLVED |
| MRgART | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- MRgART radiation therapy
- description
- Participants randomized to this arm will receive magnetic resonance-guided adaptive radiation therapy (MRgART)
- interventionNames
- Radiation: MRgART
- type
- EXPERIMENTAL
- label
- LINAC radiation therapy
- description
- Participants randomized to this arm will receive linear accelerator (LINAC) radiation therapy
- interventionNames
- Radiation: LINAC
Primary outcomes (1)
- measure
- Change in left ventricular ejection fraction (LVEF)
- timeFrame
- Pre-treatment, 3 months post-treatment, 6 months post-treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years at the time of consent. * Dosimetric eligibility criteria met using endpoints from QUANTEC (\>10% of heart receives \> 25 Gy) as determined through rapid auto-planning * Participants with histologically or cytologically proven AJCC, 8th edition including: * Stage IIB, IIIA, IIIB, IIIC, or IV non-operable non-small cell lung cancer * Limited stage small cell lung cancer, once daily treatment (excluding twice per day fractionation schemes). Stage I-III N0-2 disease esophageal/esophagogastric cancer * Stage II or III thymoma/thymic carcinoma * Other cancers in the thoracic region that meet the dosimetric and other clinical trial criteria, for example lymphoma sarcoma. * Participants must have a course of daily fractionated RT planned of at least 15 treatment fractions, typically ranging from 1.8 to 4 Gy/fraction Exclusion Criteria: * Definitive clinical or radiologic evidence of metastatic disease with life expectancy \<12 months * Prior thoracic radiotherapy significantly overlapping the heart region * Contraindications to MRI * Severe, active co-morbidity defined as follows: New York Heart Association Functional Classification III/IV are not eligible.
References
Publications (0)
Data not yet available